Breakthrough Pancreatic Cancer Drug Shows Promise in Clinical Trials
The Facts
A new experimental drug called daraxonrasib showed promising results in clinical trials for patients with advanced pancreatic cancer. The treatment nearly doubled survival time for patients with previously treated metastatic pancreatic cancer who have RAS mutations. The results come from a trial involving 168 patients.
How different outlets are framing this
Both ABC News and Fox News present the pancreatic cancer drug trial results in a notably optimistic tone, emphasizing the breakthrough nature of the findings. ABC News frames the story around 'new hope' and describes it as a 'major trial,' focusing on the Phase 3 designation which typically indicates more advanced testing. Fox News emphasizes the practical aspect by highlighting that it's a 'daily pill' and describes it as a 'breakthrough trial,' though they refer to it as a 'first-in-human trial' rather than Phase 3. Both outlets lead with the survival doubling statistic, presenting it as the primary measure of success. Neither outlet appears to emphasize potential limitations, side effects, or the typical cautionary language often associated with early-stage medical research, suggesting both are framing this as an unambiguously positive development in cancer treatment.
Source Articles
- Fox News1 Jun, 17:37New pancreatic cancer pill nearly doubles survival time in breakthrough trial
A new daily pill called daraxonrasib is showing promise against advanced pancreatic cancer in a first-in-human trial of 168 patients with RAS mutations.
- ABC News1 Jun, 12:13Experimental pancreatic cancer drug offers new hope in major trial
Phase 3 results showed the treatment nearly doubled survival for patients with previously treated metastatic pancreatic cancer.